News Releases
- July 24, 2024Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
- July 16, 2024Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
- July 9, 2024Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
- July 2, 2024Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
- June 27, 2024Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
- June 26, 2024Annovis Bio Files Patent for New Composition of Matter for Buntanetap
- June 25, 2024Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
- June 18, 2024Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
- June 11, 2024Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
- June 5, 2024Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top